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Key Clinical Message
Based upon the clinical behavior of three patients, we suggest that the combina-
tion of low-dose Ara-C and all-trans retinoic acid may potentially be effective
in some elderly patients, unfit for intensive chemotherapy, affected with NPM1-
mutated acute myeloid leukemia without FLT3 mutations, warranting perspec-
tive clinical studies in these selected patients.
Keywords
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Introduction
The addition of pharmacological doses of all-trans reti-
noic acid (ATRA) to chemotherapy has clearly revolution-
ized the clinical outcome of acute promyelocytic leukemia
(APL) [1]. In vitro observations have also suggested that
exposure to ATRA may sensitize both non-APL acute
myeloid leukemia (AML) cell lines and primary cells to
cytotoxic agents, such as Ara-C and anthracyclines,
thereby increasing either differentiation or apoptosis, by
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down-regulation of Bcl2 and related proteins [1, 2]. Based
upon these preclinical data demonstrating a synergistic
effect of ATRA combined with chemotherapy, several
clinical studies, including large randomized trials
(Table S1), have investigated the impact of adding ATRA
to either remission induction chemotherapy or lower
intensity regimens in patients with non-APL AML, but
these studies have overall yielded inconsistent and con-
flicting results [1]. However, making direct comparisons
between studies reporting discrepant clinical outcomes is
difficult because of different patient age, leukemia charac-
teristics, chemotherapy regimens and schedule of ATRA
administration [1, 3–5].
Low-dose Ara-C (LDAC) has been widely used with dif-
ferent schedules within phase II trials for elderly patients
with AML considered unfit for intensive chemotherapy,
obtaining complete remission (CR) in about 20% of cases,
but with unsatisfactory two-year overall survival (OS) rates
of approximately 10% [2]. LDAC has become the proto-
type for low-intensity chemotherapy after the randomized
trial by Burnett et al. in which LDAC produced higher CR
rate (18% vs. 1%) and better OS, when compared to pallia-
tive hydroxyurea [2]. However, median OS (5 months) was
still poor for the LDAC cohort and survival advantage was
not recorded for patients with adverse cytogenetics, in
whom CR was never achieved. Moreover, in this study, the
addition of ATRA to either of the treatment arms had no
beneficial effect on OS [2]. Conversely, some previous stud-
ies had shown positive effects of combining ATRA with
LDAC, also in poor risk patients with AML unsuitable for
aggressive chemotherapy [6, 7]. Venditti et al. reported a
high CR rate (48%) in 33 patients with poor prognosis
AML, either at disease onset or relapsed/refractory [6].
Moreover, in the retrospective study on 28 patients by Di
Febo et al., a significant improvement in OS was observed,
compared with LDAC alone, although the combination
treatment did not increase the CR rate [7]. Unfortunately,
none of these studies focused on the presence of NPM1
gene mutations in leukemic cells [2, 6, 7]. Of note, retro-
spective molecular examinations on archival samples would
potentially be of interest in order to precisely evaluate the
clinical impact of ATRA combined with LDAC in specific
molecular subgroups of unfit patients with AML [2, 6, 7].
Case Reports
We report on three elderly patients affected with cytoge-
netically normal NPM1-mutated AML, without FLT3 and
IDH1-R132 mutations, considered unfit for intensive
chemotherapy, because of advanced age and/or comorbidi-
ties (Table 1), who received moderate intensity treatment
consisting of LDAC combined with ATRA. Patients have
been hospitalized at AML diagnosis and received the first
treatment course as inpatients. In details, LDAC 20 mg
was administered subcutaneously twice daily on days 1–10,
while ATRA 45 mg/m2/day was given orally for 60 days
(from day +3 to +62). Patients 1, 2, and 3 have spent 24,
22, and 20 days in the hospital, respectively, thereafter they
were discharged and safely managed in an outpatient set-
ting. Subsequent LDAC cycles have been administered,
after intervals of 4 weeks, while each subsequent ATRA
course has been started after 1 month interval (e.g., second
ATRA course starting from day +3 of the fourth LDAC
cycle). After two LDAC cycles combined with one ATRA
course, morphologic CR was documented on bone marrow
(BM) aspirate in patients 1 and 3, whereas in patient 2,
BM aspirate was unfortunately not performed. However,
in this latter patient, normal WBC and platelet counts,
without circulating blasts, were obtained, with a concur-
rent reduction of RBC transfusion requirement. Unfortu-
nately, on day +6 of the fourth LDAC cycle, disease
progression was observed with WBC count 64.8 9 109/L
and 70% circulating blasts, Hb 8.1 g/dL, Plt count
12 9 109/L. The patient died a few days later, 5 months
since AML diagnosis. Patient 1 underwent nine LDAC
cycles combined with three ATRA courses without experi-
encing any complication; then, treatment was withdrawn,
while persisting morphologic CR. However, 9 months after
therapy interruption, leukemia relapsed with circulating
and BM blast counts 2% and 15%, respectively. Retreat-
ment with the same previously administered cytotoxic reg-
imen was attempted. The patient then received LDAC
(four cycles) and ATRA (two courses) and 2 months after
initiation of therapy, full hematologic recovery was docu-
mented, concurrently with a reduction in BM blast count
(5–10%). However, the patient subsequently suffered from
pneumonia, sinusitis and hematuria secondary to bladder
mucosal lesions, with successive occurrence of pancytope-
nia, and died 8 and 26 months after relapse and first AML
diagnosis, respectively. Patient 3 showed transient grade 2
gastrointestinal toxicity during first LDAC cycle, without
any further relevant toxicity, until leukemia relapse was
documented while receiving the tenth LDAC and third
ATRA courses, respectively. He died a few weeks later,
11 months since initial diagnosis. Unfortunately, we have
not measured quality of life (QoL) with validated instru-
ments in these three patients.
Other AML patients, in particular with NPM1 wild
type, unfit for intensive chemotherapy, have not been
treated with the same therapeutic strategy (LDAC +
ATRA) at our Institution.
Discussion
Several experimental evidence supports the modulation of
the retinoic acid-signaling pathway as a potential target
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for therapy in NPM1-mutated AML [8–12]. Earlier
in vitro studies by Martelli et al. showed that pharmaco-
logical doses of ATRA induced cell cycle arrest and apop-
tosis in both NPM1-mutated cell line OCI-AML3 and
primary leukemic cells propagated in NOD-SCID mice,
by selectively down-regulating the NPM1 mutant protein
at post-transcriptional level [8]. Moreover, Kutny et al.
demonstrated that NPM1-mutated AML cells may also be
susceptible, in vitro, to the pro-differentiating properties
of ATRA [9]. Further in vitro findings also suggested that
targeted depletion of NPM1 protein may selectively sensi-
tize NPM1-mutated AML cells to Ara-C and ATRA [10].
Of note, it has recently been reported that exposure of
NPM1-mutated AML cells to ATRA and arsenic trioxide
(ATO) induces selective proteasome-mediated degrada-
tion of NPM1 mutant protein accompanied by nucleolar
redistribution of wild-type NPM1, reversal of the charac-
teristic disorganization of PML bodies and pronounced
apoptosis and/or differentiation [11, 12]. Strikingly,
NPM1 mutant protein down-regulation by ATRA/ATO
was shown to potentiate response to daunorubicin [11].
Available information on the clinical use of ATRA in
adjunct to other antileukemic treatments in NPM1-
mutated patients with AML is summarized in Table 2
[3–5, 12–18]. Interestingly, in a retrospective biomarker
analysis within the randomized HD98B trial, Schlenk
et al. showed that the addition of ATRA to conventional
chemotherapy, including etoposide, significantly improved
event-free survival and OS only in the subgroup of elderly
patients with NPM1-mutated AML without FLT3-ITD
mutation [3]. Furthermore, preliminary data from the
prospective randomized treatment trial AMLSG 07-04 for
younger patients with AML seem to confirm the results
obtained in elderly patients [18]. In details, the beneficial
effect of ATRA on OS in the whole cohort could be
attributed to patients with favorable risk AML, including
NPM1-mutated AML in the absence of FLT3-ITD [18].
Intriguingly, biological observations from these series sug-
gested that repressor activity on retinoic acid signaling
induced by high-PRAME levels may be overcome by the
addition of ATRA [19]. Conversely, the randomized MRC
AML12 trial for patients AML <60 years of age did not
identify any molecular subgroup, defined by mutations in
NPM1, FLT3, CEBPA genes, likely to derive a significant
survival benefit from the addition of ATRA to aggressive
chemotherapy [4]. Consistently, in an analysis stratified
by etoposide addition and NPM1/FLT3 mutational status,
there was no significant improvement in clinical out-
comes by the addition of ATRA to intensive chemother-
apy for any subgroup of older patients enrolled in NCRI
AML16 trial [15]. Moreover, Nazha et al. observed that
the addition of ATRA to chemotherapy did not affect
overall outcome of patients with AML regardless of
NPM1 mutational status [5]. However, it should be noted
that limitations of this study include the small sample size
(20 NPM1-mutated patients with AML) and that other
gene mutations, such as FLT3-ITD, have not been investi-
gated in this retrospective analysis [5]. Overall, there is
currently no consensus as to whether the addition of
ATRA to chemotherapy improves the clinical outcome of
NPM1-mutated patients with AML (Table 2) [1, 3–5, 15,
18]. Of note, dosing schedule and timing of ATRA
administration, namely before, simultaneously or after
exposure to conventional chemotherapy, may be relevant
to explain discrepancies observed in different series [3–5,
15, 18]. Of interest, in vitro experiments indicated that
synergistic effects on cell viability were only observed
when ATRA was given after exposure to cytotoxic drugs
[3]. Indeed, in our three patients, such as in Austrian-
German trials, ATRA administration has been started a
few days after chemotherapy, a timepoint when leukemic
cells have already been exposed to a significant cytotoxic
effect [3, 18]. However, in addition to the potential effi-
cacy of LDAC in association with ATRA, we acknowledge
that the relatively favorable clinical outcome observed in
two of our three elderly patients with AML, may also
have been attributed to the less aggressive molecular fea-
tures, namely NPM1 gene mutation without FLT3 gene
mutations, documented in leukemic cells [20–23].
Despite the huge amount of data, although conflicting,
regarding NPM1-mutated patients with AML treated with
ATRA combined with intensive chemotherapy, scanty
information is so far available on the association of ATRA
and LDAC in this molecular subgroup of patients, when
elderly and fragile [14]. Based upon our clinical observa-
tions, we suggest that the combination of LDAC and
ATRA may potentially be effective in some elderly
patients, unfit for intensive chemotherapy, affected with
NPM1-mutated AML without FLT3 mutations, a rela-
tively good prognosis AML. Although IDH1-R132 muta-
tion has not been documented in our patients, it should
be noted that ATRA at clinically achievable doses has
recently been shown to markedly enhance terminal granu-
locytic differentiation in vitro, in either AML cell lines or
primary patient samples carrying mutant IDH1 [24].
Moreover, a potent antileukemic effect of ATRA was
observed in the presence of IDH1-R132H mutation in a
xenograft mouse model, suggesting that IDH1-R132
mutation could be a valuable biomarker to select patients
with AML for ATRA treatment [24].
Perspective randomized clinical trials are warranted to
compare LDAC alone versus LDAC combined with ATRA
and/or ATO, in order to clarify the exact role of such
treatments in these selected genetic subsets of fragile
patients [25]. In addition to the assessment of the efficacy
in terms of response rates and survival, further endpoints,
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Table 2. Clinical use of ATRA in patient with NPM1-mutated AML: review of the literature.
Reference
Number of patients/clinical
characteristics Treatment schedule Outcome Comments
Hutter
et al.,
2008 [13]
A total of 171 elderly
patients with NPM1-
mutated AML enrolled in
two consecutive AMLSG
protocols and included in a
retrospective analysis.
Seventy-eight patients
(median age 67.8 years)
from trial A, AML HD98B.
Ninety-three patients (median
age 67.9 years) from trial B,
AMLSG 06-04, in which
idarubicin was intensified in
induction therapy and
etoposide was omitted.
37% and 94% of patients
received ATRA in trials A
and B, respectively.
CR 68% and 71% in trials A
and B, respectively. No
significant difference in OS
between the two cohorts.
Restricting the analysis to
patients who received
ATRA, better EFS and DFS
for NPM1-mutated/FLT3-ITD
negative patients in trial A
compared to trial B.
Etoposide in combination
with ATRA may exert a
beneficial synergistic effect
in elderly patients with AML
having NPM1 mutation
without concurrent FLT3-
ITD.
Schlenk
et al.,
2009 [3]
A total of 377 patients with
de novo or secondary AML,
enrolled into the
randomized AMLSG HD98B
treatment trial. Median age
67 years (range 61–84).
NPM1 mutations present in
60 of the 254 analyzed
samples (24%).
Two induction cycles with
idarubicin, standard-dose
cytarabine and etoposide
with or without ATRA
(45 mg/m2 on days 3–5 and
then 15 mg/m2 on days 6–
28), followed by one
consolidation cycle of
intermediate-dose
cytarabine and
mitoxantrone with or
without ATRA (15 mg/m2
on days 6–28). For second
consolidation, patients were
randomized to either
intensive therapy with
idarubicin and etoposide or
oral maintenance therapy.
Patients randomized to ATRA
had significantly better RFS
and OS, with 4-years RFS
and OS rates 20.9% and
10.8%, respectively, as
compared to 4.8% and 5%,
respectively, in the standard
treatment arm.
A significant interaction
between NPM1-mutated
AML without FLT3-ITD and
treatment with ATRA was
identified, in that the
beneficial effect of ATRA on
RFS and OS was restricted
to this subgroup of patients.
Burnett
et al.,
2010 [4]
A total of 1075 adult
patients with AML, enrolled
in MRC AML12 randomized
protocol. Median age
48 years (range 14–68).
FLT3-ITD mutations were
present in 137 (23%) and
NPM1 mutations in 207
(35%) of the 592 patients
with available molecular
data. Patients with NPM1
and FLT3 mutations were
equally distributed between
treatment groups.
Randomization in induction
to two courses of
daunorubicin 50 mg/m2 on
days 1,3,5, thioguanine
100 mg/m2 every 12 h on
day 10 in course 1 and on
day 8 in course 2,
cytarabine at a dose of
either 100 mg/m2 (standard
DAT) or 200 mg/m2 (high
DAT) every 12 h on days 1–
10 in course 1 and days 1–8
in course 2, each with or
without ATRA 45 mg/m2/
day on days 1–60.
Subsequently, patients
received consolidation with
course 3 (amsacrine,
cytarabine, etoposide) and
were randomized between
one or two further courses,
and to chemotherapy versus
transplant.
Overall, there was no effect
from the addition of ATRA
(CR + CRi 83% with vs.
84% without ATRA; 8-year
OS 33% with vs. 30%
without ATRA).
The effect of ATRA was not
significantly different in any
of the four subgroups
defined by the combination
of FLT3 and NPM1 status. In
NPM1-mutated AML
without FLT3-ITD patients
eight-year OS was 56%
with ATRA and 40%
without ATRA, but the
difference was not
statistically significant. There
was a suggestion that ATRA
reduced relapse in patients
with lower MN1 levels, but
no significant effect on OS
was observed. This study
did not identify any
subgroup of patients likely
to derive a significant
survival benefit from the
addition of ATRA.
(Continued)
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Table 2. Continued.
Reference
Number of patients/clinical
characteristics Treatment schedule Outcome Comments
Fredly
et al.,
2013 [14]
Thirty-six patients with either
previously untreated (de
novo or secondary) or
relapsed AML, unfit for
conventional intensive
chemotherapy. Median age
77 years (range 48–90).
NPM1 and FLT3-ITD
mutations documented in
35% (13) and 40% (14) of
the cases, respectively.
On day 1, initial intravenous
loading dose of VPA, then
oral therapy 300 mg twice
daily, continued indefinitely
to maintain therapeutic
concentrations. ATRA
21.5 mg/m2 twice daily on
days 8–22 and repeated
every 12th week. LDAC
10 mg/m2/day on days 15–
24 and then repeated every
12th week.
Overall, 11 of 36 patients
showed response to
treatment (2 CR, 9 HI). The
most common response was
increased and stabilized
platelet counts. Median
survival 171 days and
33 days in responders and
nonresponders, respectively.
Detailed clinical outcome of
NPM1-mutated patients
with AML is not reported.
Disease stabilization was
seen in a subset of patients
with AML. No significant
differences with regard to
age, gender, PB counts, de
novo versus secondary AML,
cytogenetic or molecular
(FLT3, NPM1) abnormalities
between responders and
nonresponders.
Nazha
et al.,
2013 [5]
Seventy patients with NK-
AML who were enrolled in
a previous phase II
randomized clinical trial and
had stored BM samples for
NPM1 mutation analysis.
Twenty (29%) patients had
NPM1 mutation. Among
them, seven patients
received ATRA +
chemotherapy.
Patients were randomly
assigned to receive, as
remission induction
treatment: (a) FAI regimen
(fludarabine 30 mg/m2 on
days 1–4, Ara-C 2 g/m2 on
days 1–4, idarubicin 12 mg/
m2 on days 2–4); (b) FAI +
G-CSF; (c) FAI + ATRA
(45 mg/m2/day); (d) FAI +
ATRA + G-CSF.
If WBC count was
<10 9 109/L, ATRA was
begun 2 days before
chemotherapy. If WBC
count was ≥ 10 9 109/L,
ATRA was begun on day 1.
ATRA administration was
continued for 3 days after
completion of
chemotherapy.
CR rate in patients with
NPM1 mutation was 71%
and 69%, with or without
ATRA, respectively. Median
OS, EFS, RFS for the entire
group were 11.5, 7, and
11.5 months, respectively.
The addition of ATRA to
induction chemotherapy did
not affect CR rate, OS, EFS,
and RFS of patients with NK
and NPM1 mutation.
Burnett
et al.,
2013 [15]
A total of 616 older patients
with either de novo or
secondary AML or high-risk
MDS, enrolled in the NCRI
AML16 trial. Median age
67 years (range 53–82).
FLT3-ITD and NPM1 data
available for 422 and 404
patients, with mutation
rates of 19% and 24%,
respectively.
Randomization to DA versus
ADE and ATRA versus no
ATRA in a 2 9 2 factorial
design. Daunorubicin
50 mg/m2 on days 1–3 and
cytarabine 100 mg/m2 every
12 h on days 1–10 (course
1) or days 1–8 (course 2).
Patients allocated to ATRA
arms, received ATRA
45 mg/m2/day for 60 days.
Etoposide in ADE arm was
given at 100 mg/m2 on
days 1–5 of courses 1 and
2.
ORR 69% and two-year
survival 35%. ORR not
different between DA and
ADE, although CR rates
were nonsignificantly lower
in patients given ATRA. At
two-years, neither OR nor
RFS differed between arms
(OS: ADE 33% vs. DA 36%;
ATRA vs. not 35% vs.
35%).
In an analysis stratified by
etoposide and by NPM1/
FLT3 risk group, there was
no significant heterogeneity
of the effect of ATRA. No
beneficial effect of ATRA in
NPM1-mutated AML
without FLT3-ITD appeared
for patients receiving ADE.
Tassara
et al.,
2014 [16]
A total of 195 elderly (range
61–83 years) patients with
either de novo or secondary
AML.
NPM1 mutations were found
in 22 and 18 of the
Randomization to receive
induction either with (VPA
group) or without (standard
group) VPA. Induction
therapy consisted of two
cycles of idarubicin 12 mg/
CR rates after induction
tended to be lower in VPA
group (40%) compared
with standard group (52%),
as a result of the higher
early death rate. After a
The addition of VPA to
intensive induction
chemotherapy and ATRA
did not result in an
improvement of CR rates,
EFS and OS, mainly as a
(Continued)
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Table 2. Continued.
Reference
Number of patients/clinical
characteristics Treatment schedule Outcome Comments
available samples from
patients in standard group
(26%) and VPA group
(22.5%), respectively
m2 on days 1–3, cytarabine
100 mg/m2 on days 1–5,
ATRA 45 mg/m2 on days 3–
5 and 15 mg/m2 day 6–28
(AIC) or by the same
chemotherapy plus VPA
400 mg twice daily (V-AIC).
After interim analyses,
idarubicin was reduced to
days 1 and 3, and VPA was
given only during the first
cycle. A second amendment
stopped randomization
because of toxicity and
inferior CR rates in V-AIC
arm. All patients in CR
received two consolidation
cycles with chemotherapy
and ATRA.
median follow-up of
84 months, five-year EFS
(2.3% in standard and
7.6% in VPA) and OS
(11.7% in standard and
11.4% in VPA) were not
different between the two
groups. However, five-year
RFS was significantly
superior in VPA group
(24.4%) compared with
standard (6.4%).
result of increased VPA-
related hematologic toxicity
and higher death rates
during second induction
cycle. Explorative subset
analyses revealed that
NPM1-mutated AML may
particularly benefit from
VPA.
Guenounou
et, 2014 [17]
Three patients, aged 16, 21
and 51 years, respectively,
affected with relapsed/
refractory NPM1-mutated
with concurrent FLT3-ITD
positivity.
Sorafenib (400 mg twice a
day) and ATRA (45 mg/m2/
day on days 1–14). Each
cycle was repeated every
28 days until progression or
toxicity. Two patients
received etoposide 150 mg/
m2 for 2 days for debulking.
Patient 1 obtained fourth CR;
sorafenib was stopped after
2 years for toxicity and
relapse occurred. Patient 2
was still in CR after
18 months of treatment
(ATRA was stopped after
11 months for liver toxicity).
Patient 3 received therapy
bridge to transplant,
without obtaining remission.
Patients with FLT3-ITD+ and
NPM1-mutated AML could
obtain unexpected
responses upon treatment
with the combination of
sorafenib and ATRA, which
could not have been
achieved with conventional
therapies (patients 1 and 2
were previously allografted).
Schlenk
et al.,
2014 [18]
A total of 1100 adult (age
18–60 years) with AML,
entered in prospective
randomized treatment trial
AMLSG 07-04. NPM1
mutation was documented
in 29% of patients.
Induction therapy consisted
of two cycles ICE (idarubicin
12 mg/m2 on days 1,3,5 or
on days 1,3 in cycle 2;
cytarabine 100 mg/m2 on
days 1–7; etoposide
100 mg/m2 on days 1–3).
For consolidation therapy,
high-risk patients received
allo-HSCT, while all other
patients were assigned to
high-dose cytarabine (18 g/
m2 per cycle). Patients were
randomized to receive ATRA
(during induction 45 mg/m2
on days 6–8, 15 mg/m2 on
days 9–21; during
consolidation 15 mg/m2 on
days 6–28).
A PP analysis revealed higher
probability for NPM1-
mutated AML patients
treated with ATRA to
achieve a CR, with longer
EFS. Explorative analysis in
all patients on OS revealed
a benefit for patients
treated with ATRA
compared to those who
have not received ATRA
(ITT, P = 0.09; PP, P = 0.01).
The beneficial effect of ATRA
on OS in the whole cohort
of younger patients could
be attributed to patients
with ELN-favorable risk
including core-binding
factor AML, AML with
CEBPAdm and NPM1-
mutated AML in the
absence of FLT3-ITD.
El Hajj
et al.,
2015 [12]
Five elderly patients with
previously untreated or
relapsed NPM1-mutated
AML, unfit for
chemotherapy.
Compassionate use of ATRA
45 mg/m2/day combined
with ATO 0.1 mg/kg/day.
BM blasts significantly
decreased in three patients
and then re-increased upon
treatment discontinuation.
One patient died from IA at
Although CRs were not
observed, ATRA + ATO
exerted a transient in vivo
antileukemic effect, with
leukemia regression in some
(Continued)
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such as transfusion requirements, achievement of transfu-
sion independence, number and duration of hospitaliza-
tions per patient year, are actually recognized as
extremely relevant, especially in clinical trials investigating
moderate intensity treatments [26]. Moreover, QoL
parameters and other patient-reported outcomes, assessed
with validated instruments, should increasingly be incor-
porated as secondary endpoints in clinical studies for
patients with AML [27].
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